The nation of Zimbabwe has declined a substantial US health deal worth $367m (£272m) over five years because of Washington's demand for confidential data.
This rejection was revealed after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government representative later explained that the United States was seeking health data for scientific study and commercial purposes but refused to share the benefits from future treatments.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more negotiations to secure a agreement suitable to all parties so the nation's vital HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court blocked a related deal with the US after concerns were raised about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral deals to enhance openness and accountability.
Based on statements, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our nation would supply the basic resources for medical research without any certainty that the resulting innovations would be available to our population if a future pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were upending systems already established through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This framework is intended to ensure that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be structured in a way that respects the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but urged that negotiations should continue considering much of the country's HIV programmes depended on external financing.
"Where technical issues exist, including those involving information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the ongoing tensions between receiving much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.